TD Private Client Wealth LLC Has $47,000 Position in DexCom, Inc. $DXCM

TD Private Client Wealth LLC lowered its stake in DexCom, Inc. (NASDAQ:DXCM) by 94.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 712 shares of the medical device company’s stock after selling 11,575 shares during the period. TD Private Client Wealth LLC’s holdings in DexCom were worth $47,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of DXCM. Brighton Jones LLC increased its holdings in shares of DexCom by 257.7% in the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after purchasing an additional 11,946 shares in the last quarter. Integrated Wealth Concepts LLC increased its holdings in shares of DexCom by 6.3% in the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after purchasing an additional 196 shares in the last quarter. Empowered Funds LLC increased its holdings in shares of DexCom by 5.4% in the first quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock valued at $577,000 after purchasing an additional 436 shares in the last quarter. Focus Partners Wealth increased its holdings in shares of DexCom by 13.2% in the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock valued at $493,000 after purchasing an additional 841 shares in the last quarter. Finally, NewEdge Advisors LLC increased its holdings in shares of DexCom by 1.4% in the second quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock valued at $1,681,000 after purchasing an additional 258 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

DXCM has been the subject of a number of analyst reports. Piper Sandler reaffirmed an “overweight” rating on shares of DexCom in a report on Thursday, February 5th. Wall Street Zen lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 10th. Mizuho set a $75.00 target price on shares of DexCom in a report on Friday, May 1st. BTIG Research reaffirmed a “buy” rating and set a $85.00 target price on shares of DexCom in a report on Monday, March 9th. Finally, Citigroup reaffirmed a “buy” rating and set a $79.00 target price (down from $84.00) on shares of DexCom in a report on Monday, May 4th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $82.21.

Insiders Place Their Bets

In other news, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total transaction of $107,168.00. Following the transaction, the executive vice president directly owned 111,204 shares of the company’s stock, valued at $7,010,300.16. This trade represents a 1.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total transaction of $60,730.12. Following the transaction, the director directly owned 25,007 shares in the company, valued at approximately $1,500,670.07. This represents a 3.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 6,112 shares of company stock worth $379,990. Insiders own 0.28% of the company’s stock.

DexCom Price Performance

DXCM opened at $72.10 on Friday. The company has a fifty day moving average price of $63.58 and a two-hundred day moving average price of $65.98. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $89.98. The firm has a market capitalization of $27.82 billion, a PE ratio of 30.81, a P/E/G ratio of 1.19 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. The company had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business’s quarterly revenue was up 15.0% compared to the same quarter last year. During the same period last year, the firm posted $0.32 earnings per share. As a group, analysts anticipate that DexCom, Inc. will post 2.57 earnings per share for the current year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.